North Carolina Breast and Cervical Cancer Control Program 2025 Services Fee Schedule (1) For the Period 01/01/2025 through 12/31/2025 (Revision #3) Created: 01/14/2025; Revised 04/16/2025

| | | 2025 | Office Fee |
|---|---------------------------------------|------------------------|------------|
| Breast Cancer Screening and Diagnostic Procedures | Code | Fee | Allowed |
| Screening | | | |
| linical breast examination | N/A | | Yes |
| creening digital breast tomosynthesis, bilateral (2) | 77063 | \$ 48.21 | No |
| | 77063TC | \$ 21.57 | |
| | 77063-26 | \$ 26.64 | |
| creening mammography, bilateral, includes CAD | 77067 | \$ 116.72 | No |
| | 77067TC | \$ 82.88 \$ 22.82 | |
| | 77067-26 | \$ 33.83 | |
| Follow-Up | | | |
| adiological examination, surgical specimen | 76098 76008TC | \$ 39.13 \$ 25.08 | No |
| | 76098TC \$ 25.08 76098-26 \$ 14.05 | | |
| agnostic mammography, unilateral, includes CAD | 77065 | \$ 114.35 | No |
| agnostie manninography, unnateral, menutes CAD | 77065TC | \$ 114.33 \$ 78.61 | 110 |
| | 77065-26 | \$ 35.75 | |
| iagnostic mammography, bilateral, includes CAD | 77066 | \$ 144.16 | No |
| | 77066TC | \$ 100.17 | |
| | 77066-26 | \$ 43.99 | |
| iagnostic digital breast tomosynthesis, unilateral or bilateral (3) | G0279 | \$ 40.72 | No |
| | G0279TC | | |
| | G0279-26 | \$ 26.64 | |
| Itrasound, complete examination of breast including axilla, | 76641 76641TC | \$ 92.98 \$ 60.42 | No |
| unilateral (4) | 76641-26 | \$ 60.42 \$ 32.56 | |
| trasound, limited examination of breast including axilla, | 76642 | \$ 77.29 | No |
| unilateral (4) | 76642TC | \$ 46.94 | 110 |
| | 76642-26 | \$ 30.34 | |
| rgical evaluation/Consultation | See Footnote (10) | (10) | Yes |
| ne needle aspiration biopsy without imaging guidance, first lesion | 10021 | \$ 91.66 | Yes |
| Each additional lesion | 10004 | \$ 48.74 | Yes |
| ne needle aspiration biopsy including ultrasound guidance, first lesion | 10005 | \$ 121.66 | Yes |
| Each additional lesion | 10006 | \$ 55.46 | Yes |
| anch biopsy of skin (including simple closure when performed), single lesion | 11104 | \$ 111.67 | Yes |
| Each additional lesion cisional biopsy of skin (e.g., wedge; including simple closure when | 11105 | \$ 53.89 | Yes |
| rformed), single lesion | 11106 | \$ 138.80 | Yes |
| Each additional lesion | 11107 | \$ 63.69 | Yes |
| incture aspiration of cyst of breast | 19000 | \$ 88.16 | Yes |
| uncture aspiration of cyst of breast, each additional cyst, used with 19000 | 19001 | \$ 24.03 | Yes |
| east biopsy, with placement of localization device and imaging of | 19081 | \$ 441.20 | Yes |
| iopsy specimen, percutaneous; stereotactic guidance; first lesion (5) Each additional lesion (5) | 19082 | \$ 334.48 | Yes |
| reast biopsy, with placement of localization device and imaging of | 19083 | \$ 436.21 | Yes |
| biopsy specimen, percutaneous; ultrasound guidance; first lesion (5) Each additional lesion (5) | 19083 | \$ 430.21 \$ 327.95 | Yes |
| | | | |
| reast biopsy, percutaneous, needle core, not using imaging guidance | 19100 | \$ 131.79 | Yes |
| reast biopsy, open, incisional | 19101 | \$ 288.23 | Yes |

North Carolina Breast and Cervical Cancer Control Program 2025 Services Fee Schedule (1)

| | | | 2025 | Office Fee |
|---|----------------|----------|----------------|------------|
| Breast Cancer Screening and Diagnostic Procedures | Code | ¢ | Fee | Allowed |
| Excision of cyst, fibroadenoma or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion; open; one or more lesions | 19120 | \$ | 474.50 | Yes |
| Excision of breast lesion identified by preoperative placement of radiological marker; open; single lesion | 19125 | \$ | 522.93 | Yes |
| Each additional lesion separately identified by a preoperative radiological marker | 19126 | \$ | 144.11 | Yes |
| Placement of breast localization device, percutaneous; mammographic guidance; first lesion (6) | 19281 | \$ | 218.11 | Yes |
| Each additional lesion (6) | 19282 | \$ | 152.38 | Yes |
| Placement of breast localization device, percutaneous; stereotactic guidance; first lesion (6) | 19283 | \$ | 231.94 | Yes |
| Each additional lesion (6) | 19284 | \$ | 166.29 | Yes |
| Placement of breast localization device, percutaneous; ultrasound guidance; first lesion (6) | 19285 | \$ | 320.22 | Yes |
| Each additional lesion (6) | 19286 | \$ | 258.95 | Yes |
| Needle biopsy of axillary lymph node | 38505 | \$ | 156.71 | Yes |
| Ultrasonic guidance for needle placement, imaging | 76942 | \$ | 54.28 | No |
| supervision and interpretation | 76942-TC | \$ | 25.97 | |
| | 76942-26 | \$ | 28.31 | |
| Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic | 88172 | \$ | 52.10 | No |
| study to determine adequacy of specimen(s), first evaluation episode | 88172TC | \$ | 19.68 | 110 |
| | 88172-26 | \$ | 32.42 | |
| Cytopathology, evaluation of fine need aspirate; immediate cytohistologic | 88177 | \$ | 27.58 | No |
| study to determine adequacy of specimen(s), each separate additional | 88177TC | \$ | 7.79 | |
| evaluation episode | 88177-26 | \$ | 19.79 | |
| Cytopathology, evaluation of fine needle aspirate; interpretation and report | 88173 | \$ | 156.78 | No |
| | 88173TC | \$ | 93.12 | |
| | 88173-26 | \$ | 63.66 | |
| Surgical pathology, gross and microscopic examination | 88305 | \$ | 66.03 | No |
| | 88305TC | \$ | 31.97 | |
| | 88305-26 | \$ | 34.06 | |
| Surgical pathology, gross and microscopic examination; requiring microscopic | 88307 | \$ | 260.81 | No |
| evaluation of surgical margins | 88307TC | \$ | 186.27 | |
| | 88307-26 | \$ | 74.54 | |
| Morphometric analysis, tumor immunohistochemistry, per specimen; manual | 88360 | \$ | 108.80 | |
| | 88360TC | \$ | 70.90 | |
| | 88360-26 | \$ | 37.89 | |
| Morphometric analysis, tumor immunohistochemistry, per specimen; | 88361 | \$ | 106.04 | |
| using computer-assisted technology | 88361TC | \$ | 66.41 | |
| | 88361-26 | \$ | 39.63 | |
| Anesthesia for procedures on the integumentary system, anterior trunk, not otherwise specified (7) | 00400 | \$ | 19.63 | |
| | | | | |
| Moderate anesthesia, 10-22 minutes for individuals 5 years or older Each additional 15 minutes (8) | 99156 99157 | \$ \$ | 68.50 53.11 | |
| Each auditional 13 minutes (6) | 77137 | \$ | 55.11 | |

North Carolina Breast and Cervical Cancer Control Program 2025 Services Fee Schedule (1)

| 2025 Services Fee Sch | | | 2025 | Office Fee |
|---|---------------------|----------|------------------|------------|
| Cervical Cancer Screening and Diagnostic Procedures | Code | | Fee | Allowed |
| Screening Pelvic examination - Bimanual | N/A | | | Yes |
| Cytopathology, cervical or vaginal, any reporting system, <i>requiring interpretation by physician</i> | 88141 | \$ | 23.00 | |
| Cytopathology (liquid-based Pap test) cervical or vaginal, collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision | 88142 | \$ | 20.26 | |
| ytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; manual screening and rescreening under physician supervision | 88143 | \$ | 23.04 | |
| Cytopathology (conventional Pap test), slides cervical or vaginal reported in Bethesda System, manual screening under physician supervision | 88164 | \$ | 18.19 | |
| Cytopathology (conventional Pap test), slides cervical or vaginal reported in Bethesda System, manual screening and rescreening under physician supervision | 88165 | \$ | 42.22 | |
| Cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision | 88174 | \$ | 25.37 | |
| ytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; screening by automated system and manual rescreening, under physician supervision | 88175 | \$ | 26.61 | |
| luman Papillomavirus, high-risk types (9) | 87624 | \$ | 35.09 | No |
| uman Papillomavirus, genotyping (9) | 87625 | \$ | 40.55 | No |
| uman Papillomavirus, reported high-risk types separately and pooled (9) | 87626 | \$ | 70.20 | No |
| Follow-Up | | | | |
| olposcopy of the cervix | 57452 | \$ | 115.39 | Yes |
| olposcopy of the cervix, with biopsy and endocervical curettage | 57454 | \$ | 154.15 | Yes |
| olposcopy of the cervix, with biopsy | 57455 | \$ | 147.46 | Yes |
| olposcopy of the cervix, with endocervical curettage | 57456 | \$ | 138.27 | Yes |
| urgical pathology, gross and microscopic examination | 88305 | \$ | 66.03 | No |
| | 88305TC | \$ | 31.97 | No |
| | 88305-26 | \$ | 34.06 | No |
| urgical pathology, gross and microscopic examination; requiring | 88307 88307TC | \$ \$ | 260.81 186.27 | No No |
| microscopic evaluation of surgical margins | 883071C 88307-26 | \$ \$ | 74.54 | No No |
| nmunohistochemistry or immunocytochemistry, per specimen; | 88342 | \$ | 102.06 | |
| initial single antibody stain procedure | 88342 88342TC | \$ | 70.60 | |
| | 88342-26 | \$ | 31.46 | |
| mmunohistochemistry or immunocytochemistry, per specimen; | 88341 | \$ | 87.51 | |
| each additional single antibody stain procedure (List separately | 88342TC | \$ \$ | 62.00 | |
| in addition to code for primary procedure) | 88341-26 | ÷ | 25.51 | |
| anesthesia for vaginal procedures (including biopsy of cervix) (7) | 00940 | \$ | 19.63 | |
| | | | | |

North Carolina Breast and Cervical Cancer Control Program 2025 Services Fee Schedule (1)

| Physician Visits | СРТ | 2025 |
|---|-------|--------------|
| Office Visits (10) | Code | Fee |
| New patient; medically appropriate history/exam, straightforward decision- making; 15-29 minutes | 99202 | \$ 66.33 |
| New patient; medically appropriate history/exam; low level decision-making; 30-44 minutes | 99203 | \$ 103.42 |
| Established patient; evaluation and management, may not require presence of physician; presenting problems are minimal | 99211 | \$ 21.31 |
| Established patient; medically appropriate history/exam, straightforward decision-making; 10-19 minutes | 99212 | \$ 52.17 |
| Established patient; medically appropriate history/exam; low level decision- making; 20-29 minutes | 99213 | \$ 84.64 |
| Established patient; medically appropriate history/exam; moderate level decision-making; 30-39 minutes | 99214 | \$ 119.25 |
| Pelvic examination (list separately, in addition to primary procedure) (12) | 99459 | \$ 19.17 |
| Administration of a standardized, evidence-based Social Determinants of Health Risk assessment, 5-15 min., not more often than every 6 mos. | G0136 | \$ 17.42 |
| Community health integration services performed by certified or trained auxiliary personnel, including a community health worker, under the direction of a physician or other practitioner; 60 min./calendar year | G0019 | \$ 74.07 |
| Community health integration services, each additional 30 min./calendar year | G0022 | \$ 46.27 |

Telephone Visits (11)

Awaiting further guidance from NBCCEDP; fee schedule to be revised accordingly. (11)

Global and Split Fees

Both global and split fees apply to the breast and cervical procedures listed on this fee schedule. The method and direction of payment will determine their usage for your facility. The following are the codes and definitions that apply:

G = Global - the all-inclusive fee for performing and interpreting the service.

TC = Technical Component - the fee for performing the service.

26 = Professional Component - the fee for interpreting the service.

- **NOTES:**
- (1) NC BCCCP covers only the physician's fee. Any facility charges associated with these CPT codes are not covered.
- (2) List separately in addition to code for primary procedure 77067.
- (3) List separately in addition to 77065 or 77066.
- (4) Bilateral ultrasound may be reimbursed at one and one-half times the unilateral rate (not double unilateral rate).
- (5) Codes 19081-19084 are to be used for breast biopsies that include image guidance, placement of a localization device, and imaging of specimen. They should not be used in conjunction with 19281-19286.
- (6) Codes 19281-19286 are for image guidance placement of a localization device without image-guided biopsy. These codes should not be used in conjunction with 19081-19084.
- (7) Fee is calculated using (Base Units + Time [in units]) x Conversion Factor = Anesthesia Fee Amount. Go to https://www.cms.gov/medicare/payment/fee-schedules/physician/anesthesiologists-center for updated base rates and conversion
- (8) Example: If procedure is 50 minutes, code 99156 + (99157 x 2). No separate charge allowed if procedure <10 minutes.
- (9) HPV DNA testing is not a reimbursable test for women under 30 years of age; 87626 cannot be reimbursed along with 87624 or 87625.
- (10) All consultations should be billed through the standard "new patient" office visit CPT codes: 99202-99205. Consultations billed as 99204 or 99205 must meet the criteria for these codes, and must be pre-authorized. Codes 99204 and 99205 are typically <u>not</u> appropriate for NC BCCCP screening visits, but may be used when provider spends extra time to do a detailed risk assessment. BCCCP may pay for up to two surgical consultations.
- (11) The National Breast & Cervical Cancer Early Detection Program (NBCCEDP) allows telehealth visits using regular office visit codes through the end of December 2025. These visits can be performed using routine technology platforms (e.g., phones, facetime, free Zoom, etc.) and relaxes the use of only HIPAA-compliant platforms. Future allowance for the use of telehealth visits will be based upon guidance we receive from NBCCEDP. By law, NC BCCCP can only cover Medicare-approved and allowable procedures.
- (12) Code 99459 may only be reimbursed if cervical cytology (Pap) or HPV test is conducted during pelvic exam.